Nature子刊：首次将人类肾脏类器官与猪肾脏融合，并成功移植到体内

Core Insights - The article discusses the promising applications of organoid technology in regenerative medicine, particularly focusing on human pluripotent stem cell (hPSC)-derived kidney organoids and their potential for clinical applications in organ transplantation and tissue regeneration [2][3]. Group 1: Research Breakthroughs - Researchers developed a scalable, reproducible, and cost-effective method to generate human kidney organoids from hPSCs, which can differentiate into various kidney cell types [6]. - The study successfully demonstrated the ex vivo transplantation of hPSC-derived kidney organoids into porcine kidneys, marking a significant milestone in regenerative medicine and personalized healthcare [3][10]. Group 2: Methodology and Findings - The research utilized single-cell RNA sequencing, confocal imaging, and CRISPR-Cas9 engineering to analyze the transcriptional diversity and cellular composition of hPSC-kidney organoids [8]. - The hPSC-kidney organoids were perfused into ex vivo pig kidneys using a room-temperature mechanical perfusion technique, confirming the feasibility and effectiveness of this approach for organ transplantation [8][11]. Group 3: Clinical Implications - The study indicates that combining organoids with ex vivo perfusion technology can facilitate controlled conditions for cell therapy, aiming to regenerate or repair organs before transplantation, thereby reducing patient wait times and increasing the availability of healthy organs [10].